Last reviewed · How we verify
Fam-Trastuzumab Deruxtecan-Nxki (TDxD) (fam-trastuzumab-deruxtecan-nxki-tdxd)
Fam-Trastuzumab Deruxtecan-Nxki (TDxD) (generic name: fam-trastuzumab-deruxtecan-nxki-tdxd) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently in Phase 2 development.
Fam-trastuzumab deruxtecan-nxki targets HER2-positive cancer cells, delivering a cytotoxic payload to induce apoptosis.
At a glance
| Generic name | fam-trastuzumab-deruxtecan-nxki-tdxd |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Mechanism of action
Fam-trastuzumab deruxtecan-nxki binds to the HER2 receptor on cancer cells, allowing the attached cytotoxic agent to enter the cell and trigger cell death, effectively targeting tumors that overexpress HER2.
Approved indications
Common side effects
Key clinical trials
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (PHASE2)
- Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fam-Trastuzumab Deruxtecan-Nxki (TDxD) CI brief — competitive landscape report
- Fam-Trastuzumab Deruxtecan-Nxki (TDxD) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI